drugset / Trial / NCT05340309
Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer
Phase 2
Active not recruiting
5 enrolled
University of Southern California
Genentech, Inc. · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial tests whether subcutaneous atezolizumab can be effectively given at home with medical care provided primarily using telemedicine in patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study may help determine if a telemedicine based approach that gives atezolizumab at home using a version of the drug designed for subcutaneous injection under the skin is safe and feasible.
Timeline
- Start
- 2022-12-07
- Primary completion
- 2026-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1875 mg | Subcutaneous |
| Background | rHuPH20 | Protein / enzyme biologic | — | Subcutaneous |